Acumen Hypotension Prediction Index – EV1000 Clinical Platform vs ASSURE Wearable ECG

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
Acumen Hypotension Prediction Index – EV1000 Clinical Platform
by Edwards Lifesciences
VS
ASSURE Wearable ECG
by Kestra Medical Technologies

AI Verdict

Tool A is designed for real-time prediction of hypotensive events in acute care settings, providing insights into hemodynamic instability and potential causes. Tool B, conversely, offers continuous wearable ECG monitoring for at-risk cardiac patients, focusing on long-term heart rate data collection and remote management. Their primary applications and the specific physiological parameters they monitor make them suitable for distinct clinical needs.

Choose Acumen Hypotension Prediction Index – EV1000 Clinical Platform if…

Choose Acumen Hypotension Prediction Index if your primary goal is real-time, proactive management of hemodynamic stability in acute care settings like the OR, ICU, or ER. This tool is ideal for clinicians who need to predict and prevent hypotensive events up to 15 minutes in advance, utilizing machine learning to guide interventions and optimize patient outcomes during surgery or in critical conditions.

View Acumen Hypotension Prediction Index – EV1000 Clinical Platform →

Choose ASSURE Wearable ECG if…

Choose ASSURE Wearable ECG if you require continuous, long-term remote heart rate monitoring and data collection for at-risk cardiac patients outside of an acute care environment. This wearable device is best suited for cardiologists looking to track arrhythmias, monitor heart rate trends, and receive alert-based notifications through a cloud-based platform, enabling comprehensive patient management from a distance.

View ASSURE Wearable ECG →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Acumen Hypotension Prediction Index – EV1000 Clinical Platform ASSURE Wearable ECG
Pricing Unknown Contact for pricing.
Deployment On-premise (integrated with EV1000 clinical platform and HemoSphere advanced monitoring platform) Wearable device, mobile application, and cloud-based remote patient data platform.
BAA Available Unknown Yes AI-estimated
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

ASSURE Wearable ECG

Tool B, the ASSURE Wearable ECG, is designed as a comfortable wearable with a mobile application and cloud platform, prioritizing patient ease of use for continuous remote monitoring. This patient-centric design, including a non-adhesive SensorFit Garment, is crucial for compliance and long-term use outside acute settings. While Tool A integrates into existing hospital systems, Tool B's focus on broad patient accessibility and comfort gives it an edge in overall usability.

Clinical Value

Acumen Hypotension Prediction Index – EV1000 Clinical Platform

Tool A, Acumen HPI, offers significant proactive clinical value by predicting hypotensive events up to 15 minutes in advance and providing insights into underlying hemodynamic causes. This capability allows for timely intervention to prevent adverse outcomes in high-acuity settings, with studies demonstrating a 57% reduction in the duration of intraoperative hypotension. Tool B, while valuable for continuous cardiac monitoring, primarily serves a diagnostic and data collection role.

Pricing & Value

Tie

Both tools require direct contact for pricing, making a transparent comparison of cost-effectiveness impossible. While Tool A has a specific finding from NICE that there is 'currently no evidence to suggest that this technology is cost saving', this does not negate its clinical value. Tool B's value is also primarily clinical, focusing on improved patient management through continuous monitoring, without explicit public data on cost savings. Due to the lack of comprehensive pricing and comparative cost-benefit analysis, a definitive winner cannot be determined.

Enterprise Readiness

Acumen Hypotension Prediction Index – EV1000 Clinical Platform

Tool A, from Edwards Lifesciences, a major medical technology company, is integrated with their established HemoSphere Advanced Monitoring Platform, indicating robust compatibility with existing hospital IT infrastructure. This deep integration and the company's long-standing presence in acute care environments suggest a higher level of proven enterprise readiness. While Tool B offers a comprehensive remote monitoring solution, integrating a new RPM system across a large enterprise can present distinct challenges.

Innovation

Acumen Hypotension Prediction Index – EV1000 Clinical Platform

Tool A demonstrates a higher degree of innovation by applying machine learning to predict critical physiological events like hypotension up to 15 minutes in advance and providing actionable insights into their root causes. This proactive, AI-driven decision support represents a significant advancement in critical care management. Tool B's innovations lie in its wearable design and advanced signal processing for data quality, which are valuable but less transformative in predictive clinical intervention.

Support & Docs

Acumen Hypotension Prediction Index – EV1000 Clinical Platform

Edwards Lifesciences, the developer of Tool A, explicitly advertises 24/7 technical support for the Acumen HPI system, along with extensive online resources and FAQs. While Kestra Medical Technologies (Tool B) provides a dedicated helpline for both patients and providers and comprehensive patient documentation, the explicit mention of 24/7 technical support for Tool A indicates a more robust and continuously available support infrastructure.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Acumen Hypotension Prediction Index – EV1000 Clinical Platform ASSURE Wearable ECG
Product Name Acumen Hypotension Prediction Index u2013 EV1000 Clinical Platform ASSURE Wearable ECG
Company Edwards Lifesciences Kestra Medical Technologies
Primary Function Predicts hypotensive events up to 15 minutes in advance, providing clinicians with insights into hemodynamic instability and potential causes. Non-therapeutic device for continuous heart rate monitoring and data collection for at-risk cardiac patients.
Target Specialties Anesthesiology, Critical Care, Emergency Medicine Cardiology
Key Feature (Prediction/Monitoring) Predicts hypotension up to 15 minutes in advance Continuous heart rate monitoring
Key Feature (Technology/Component) Machine learning-based algorithm for prediction ASSURE Detection Algorithm with Quad Channel Processingu2122

Videos

Demos, reviews, and walkthroughs featuring Acumen Hypotension Prediction Index – EV1000 Clinical Platform and ASSURE Wearable ECG.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Acumen HPI is designed for real-time, proactive management of hemodynamic instability and hypotension in surgical and critical care settings, providing predictive insights up to 15 minutes in advance and guidance on potential causes. In contrast, the ASSURE Wearable ECG focuses on continuous, remote heart rate monitoring and data collection for at-risk cardiac patients, supporting long-term management and detection of cardiac events outside the hospital.
Acumen HPI integrates with Edwards Lifesciences' HemoSphere platform, and studies involving it have utilized automated extraction of device-captured and manually entered EHR data, including physiologic parameters. The ASSURE Wearable ECG's Kestra CareStation remote patient data platform is designed to summarize relevant patient data for healthcare providers and can integrate with EHRs, HL7, and FHIR through plugins.
Acumen HPI uses a machine learning-based algorithm that analyzes arterial pressure waveforms to predict hypotension with high sensitivity and specificity, demonstrating superior predictive performance over common hemodynamic parameters. The ASSURE Wearable ECG employs the ASSURE Detection Algorithm with Quad Channel Processing and Adaptive Patient Intelligence, a proprietary technology that adapts to the patient's heart rhythm to filter out motion artifacts and enhance accuracy of continuous ECG monitoring.
For Acumen HPI, clinicians would learn to interpret the HPI parameter, Smart Alerts, and Relationship View to guide interventions, with studies showing a reduction in hypotension duration with protocolized treatment. For ASSURE Wearable ECG, the learning curve primarily involves familiarization with the Kestra CareStation platform for data review and alert management, with value realized through efficient remote monitoring and earlier detection of cardiac events.
The ASSURE Wearable ECG system, through the Kestra CareStation platform, implements security features such as encryption, audit logs, firewalls, IDS/IPS, VPN, and endpoint security, with audit trails likely available for clinician access and alert review. While specific details for Acumen HPI beyond HIPAA are not provided in the given facts, general best practices for securing ECG data in healthcare include access controls, audit logging, and integrity protections.
For Acumen HPI, multi-site rollout would involve integrating with existing Edwards Lifesciences HemoSphere platforms and ensuring consistent sensor deployment (Acumen IQ cuff or sensor) across operating rooms or ICUs. For ASSURE Wearable ECG, considerations would include managing wearable devices, mobile applications, and the cloud-based Kestra CareStation platform across various outpatient cardiology clinics, with a focus on patient onboarding and remote data management.
Edwards Lifesciences is committed to providing high levels of customer service and support for Acumen HPI, including clinical education resources and 24/7 technical support. Kestra Medical Technologies offers the ASSURE Assist service for post-event support and has presented real-world data and case studies, such as the ACE-PAS trial, demonstrating clinical performance and patient engagement.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform
AISAP Cardio vs Rapid Enterprise Platform
AngioWaveNet vs Rapid Enterprise Platform
CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Acumen Hypotension Prediction Index – EV1000 Clinical Platform or ASSURE Wearable ECG

Backers

Who funded each tool's parent company.

ASSURE Wearable ECG

AI Tool Finder
AI-powered search. Results may not be comprehensive.